This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Artiva Biotherapeutics, Inc. (ARTV) and Emergent Biosolutions (EBS)

Tipranks - Tipranks - Tue May 5, 5:32AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Assembly Biosciences (ASMB), Artiva Biotherapeutics, Inc. (ARTV) and Emergent Biosolutions (EBS) with bullish sentiments.

Claim 55% Off TipRanks

Assembly Biosciences (ASMB)

H.C. Wainwright analyst Patrick Trucchio reiterated a Buy rating on Assembly Biosciences today and set a price target of $50.00. The company’s shares closed last Friday at $27.37.

According to TipRanks.com, Trucchio is a 5-star analyst with an average return of 24.5% and a 51.4% success rate. Trucchio covers the Healthcare sector, focusing on stocks such as Harmony Biosciences Holdings, Arrowhead Pharmaceuticals, and Alto Neuroscience, Inc. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Assembly Biosciences with a $44.33 average price target.

See Insiders’ Hot Stocks on TipRanks >>

Artiva Biotherapeutics, Inc. (ARTV)

In a report released today, Gil Blum from Needham reiterated a Buy rating on Artiva Biotherapeutics, Inc., with a price target of $18.00. The company’s shares closed last Friday at $10.80.

According to TipRanks.com, Blum is a 5-star analyst with an average return of 11.7% and a 41.0% success rate. Blum covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Mereo Biopharma Group Plc, and Crispr Therapeutics AG. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Artiva Biotherapeutics, Inc. with a $17.00 average price target.

Emergent Biosolutions (EBS)

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Emergent Biosolutions today and set a price target of $12.00. The company’s shares closed last Friday at $8.47.

According to TipRanks.com, Selvaraju is a 5-star analyst with an average return of 23.1% and a 55.0% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding, Aardvark Therapeutics, Inc., and MoonLake Immunotherapeutics. ;'>

Currently, the analyst consensus on Emergent Biosolutions is a Moderate Buy with an average price target of $12.00.

Read More on ASMB:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).